Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study ...

Patients with vision loss caused by a common but untreatable condition are able to read again thanks to a groundbreaking eye implant. The Prima device is an electronic eye implant which measures just ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in ...

Discover a study linking allergic rhinitis to a higher risk of optic neuritis, revealing shared inflammatory pathways and key ...

– Data provide insights that informed the Phase 1 study of STK-002 as a potential disease-modifying medicine for ADOA, including disease etiology, progression and clinical assessments – – ADOA is a ...

A noninvasive MRI technique that measures volumetric changes in paraspinal muscles could transform how doctors assess nerve damage in the cervical spine, which helps guide more precise treatment ...

Prima, developed by US medtech company Science Corporation, comprises a tiny chip, measuring about 2mm by 2mm and the same thickness as a human hair, as well as augmented reality glasses and a pocket ...

Researchers identified two specific problems that led to vision loss among these patients. One group’s papilledema led to ...

Guillain-Barré Syndrome, or GBS, is a rare neurological condition. The body's immune system mistakenly attacks its own nerves. This can lead to rapid muscle weakness and paralysis. Early symptoms ...